Search research articles
Contact Us
Filters
Showing results (171-180 of 201) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2021
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Andrew B Lassman, Patrick Y Wen, Martin J van den Bent, et al.
Science Translational Medicine
|
October 11, 2023
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma
Kavita Y Sarin, John Kincaid, Brittney Sell, et al.
Journal of Medical Genetics
|
June 25, 2015
Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2
Stavros M Stivaros, Anat O Stemmer-Rachamimov, Robert Alston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Neuro-Oncology
|
April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Andrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
Acta Neuropathologica
|
October 7, 2020
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis
Sheila Mansouri, Suganth Suppiah, Yasin Mamatjan, et al.
Acta Neuropathologica
|
October 28, 2020
Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis
Sheila Mansouri, Suganth Suppiah, Yasin Mamatjan, et al.
Blood
|
July 15, 2025
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy
Leon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson, et al.
Molecular Cancer Therapeutics
|
July 5, 2021
Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma
Matthias A Karajannis, Audrey Mauguen, Ekrem Maloku, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 201) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2021
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Andrew B Lassman, Patrick Y Wen, Martin J van den Bent, et al.
Science Translational Medicine
|
October 11, 2023
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma
Kavita Y Sarin, John Kincaid, Brittney Sell, et al.
Journal of Medical Genetics
|
June 25, 2015
Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2
Stavros M Stivaros, Anat O Stemmer-Rachamimov, Robert Alston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Neuro-Oncology
|
April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Andrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
Acta Neuropathologica
|
October 7, 2020
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis
Sheila Mansouri, Suganth Suppiah, Yasin Mamatjan, et al.
Acta Neuropathologica
|
October 28, 2020
Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis
Sheila Mansouri, Suganth Suppiah, Yasin Mamatjan, et al.
Blood
|
July 15, 2025
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy
Leon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson, et al.
Molecular Cancer Therapeutics
|
July 5, 2021
Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma
Matthias A Karajannis, Audrey Mauguen, Ekrem Maloku, et al.
Page
of 21